Johnson & Johnson is paying $3.05 billion to acquire Halda Therapeutics, obtaining a novel cell death platform while strengthening its prostate cancer franchise built on Erleada.

Researchers have discovered that prostate cancer depends on two key enzymes, PDIA1 and PDIA5, to survive and resist therapy. When blocked, these enzymes cause the androgen receptor to collapse, killing cancer cells and enhancing the effects of drugs like enzalutamide.

Phase 3 ARENSENS clinical trial results were presented at JADPRO 2025, indicating darolutamide plus ADT improved rPFS in prostate cancer.

Promoting awareness among friends and family and advocating for improved access to screening services, including free or low-cost testing and public education, can help reduce late-stage diagnoses.

The Island Prostate Centre in Victoria is celebrating 25 years of providing services and support to men and their families going through a prostate cancer diagnosis.

The EMA’s assessment confirms the treatment matches the reference drug in quality and performance, potentially expanding access for patients across the EU.

Prostate cancer, the second leading cause of cancer death in men, sees advancements in treatment that reduce side effects, encouraging more men to undergo screening.

Prostate cancer is the most common cancer among men, and it's the second leading cause of cancer death for men in the U.S.